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Objective: Although the clinical relevance of minor depression has
been demonstrated in many studies, the economic costs are not well
explored. In this study, we examine the economic costs of minor
depression.
Method: In a large-scale, population-based study in the Netherlands
(n ¼ 5504) the costs of minor depression were compared with the costs
of major depression and dysthymia. Excess costs, i.e. the costs of a
disorder over and above the costs attributable to other illnesses, were
estimated with help of regression analysis. The direct medical costs, the
direct non-medical costs and the indirect non-medical costs were
calculated. The year 2003 was used as the reference year.
Results: The annual per capita excess costs of minor depression were
US$ 2141 (95% CI ¼ 753–3529) higher than the base rate costs of US$
1023, while the costs of major depression were US$ 3313 (95% CI ¼
1234–5390) higher than the base rate. The costs of minor depression
per 1 million inhabitants were 160 million dollars per year, which is
somewhat less than the costs of major depression (192 million dollars
per year).
Conclusion: The economic costs associated with minor depression are
considerable and approach those of major depression.
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Significant outcomes
• The annual excess per capita costs of minor depression are about two-thirds of the per capita costs of
major depression.
• Per million inhabitants the excess costs of minor depression (US$ 160 million) approach those of
major depression (US$ 192 million).
• Virtually all excess costs of minor depression are indirect non-medical costs (costs for treatment are
not signiﬁcantly higher than the base rate).
Limitations
• The deﬁnition of minor depression was not exactly the same as the DSM-IV deﬁnition.
• Although the number of subjects was large, it is relatively small for economic studies.
• Data from the second measurement point of the study were used, at which point some attrition had
already taken place.
Introduction
Minor depression is a highly prevalent condition
(1, 2), with a considerable impact on the quality of
life of patients (3, 4), and resulting in an increased
utilization of medical services (5). Minor depres-
sion is also associated with an increased mortality
rate (6, 7) and carries a high risk of developing
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major depressive disorder on both the short (2) and
the long term (8, 9).
Despite these indications of clinical relevance, it
is less clear whether minor depression is associated
with increased economic costs. Although major
depressive disorder is associated with considerable
economic costs (10, 11), as are other mental
disorders (12–14), the costs of minor depression
remain unclear.
The few studies that have examined the econo-
mic burden of minor depression have reported
increased service utilization and high medical costs
in adults (5, 15–17) and among elderly (18–20).
However, most of these studies focused exclusively
on direct medical costs, thereby ignoring patients
out-of-pocket and time costs, and ignoring the
often very substantial costs of production losses.
Furthermore, several of these studies do not deﬁne
minor depression according to diagnostic criteria
but are based on self-reported symptoms. Most
studies have focused on patients with minor
depression who sought help for their problems,
thereby ignoring those subjects who do not seek
treatment. Finally, none of the studies has used a
random sample of community residents with minor
depression.
Aims of the study
To examine in a large, representative sample of the
Dutch population whether minor depression is
associated with signiﬁcantly increased medical and
non-medical costs. Furthermore, it was hypothes-
ized that the costs of minor depression would be
substantially smaller than those of major depres-
sion and dysthymia, which are generally considered
to be more disabling. The study also examined
whether there is a dose–response relationship
between the number of depressive symptoms and
economic costs and whether speciﬁc symptoms are
associated with excess costs.
Material and methods
Subjects and procedure
This cost-of-illness study was conducted using the
data of the Netherlands Mental Health Survey and
Incidence Study (NEMESIS) which has been
described in detail elsewhere (21), and is part of a
series of studies on the costs of mental disorders. In
brief, a random, stratiﬁed, multistage sample was
obtained in three steps at baseline (t0). First,
municipalities were stratiﬁed by urbanization, and
90 municipalities were drawn randomly and pro-
portionately from these strata. Second, within each
municipality, households were randomly drawn
from the postal register. Finally, within each
household the person with the most recent birth-
day was selected on condition that he or she was
aged between 18 and 65 years and sufﬁciently
ﬂuent in Dutch to be interviewed. Eligible persons
who were not immediately available were contac-
ted later in the year. The response rate was 69.7%
resulting in a sample of 7076 people at t0. The
baseline sample followed the same multivariate
distribution over age, sex, civil status and urbanity
as the general Dutch population; however, males in
the age group 18–24 years were slightly under-
represented. All data were collected in structured
face-to-face interviews.
At ﬁrst follow-up (t1), which occurred 1 year
(M ¼ 379 days, SD ¼ 35) after baseline measure-
ment, 5618 persons (79.4%) continued their parti-
cipation. The present study is based on the t1
sample because minor depression and medical
consumption were measured at t1 (and not, or
not sufﬁciently, at t0). Because we wanted to
control for common mental disorders, we excluded
from the analyses 114 subjects with DSM-III-R
mental disorders with a 1-year prevalence below
1% (as measured with the Composite International
Diagnostic Interview (CIDI), see below: bipolar
disorder, obsessive–compulsive disorder, eating
disorders and schizophrenia). This resulted in an
effective sample size of n ¼ 5504.
Of this sample, 49% were women; the mean age
was 40 (range 18–65 years); 69% was living with a
partner; 5% had elementary education, 35% lower
vocational, 30% secondary and 30% had higher
vocational and academic education; 94% was born
in the Netherlands; and 70% was employed.
We evaluated the eﬀect of attrition from t0 to t1
and found no evidence that it was related to having
a mental disorder at t0 but, again, the younger
males were more likely to be lost to follow-up (22).
Corrective weights were used to improve general-
izability (see Analysis).
Measures
DSM-III-R axis-I disorders were assessed in both
waves with CIDI (23), Dutch 1.1 version (24). The
CIDI is a fully computerized psychiatric interview
and can be used by trained interviewers who are
not clinicians. It has an acceptable inter-rater and
test–retest reliability for the disorders under study
(25).
In this study, the following disorders were
examined: depressive disorder, dysthymia, anxiety
disorder (presence of panic disorder with and
without agoraphobia, generalized anxiety disorder,
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simple phobia, social phobia and/or agoraphobia
without a history of panic) and alcohol-related
disorder (alcohol misuse and/or alcohol depend-
ence).
Minor depression. Because the CIDI does not
provide an algorithm for the diagnosis of minor
depression, we used a deﬁnition which best
approached the DSM-IV deﬁnition. We deﬁned
minor depression as the subject reporting one of
the core symptoms of depression between t0 and t1
during at least 2 weeks, plus at least one other
symptom, but the total number of symptoms not
exceeding four.
Major depression was deﬁned according to the
DSM-III-R classiﬁcation and measured with the
CIDI.
Chronic medical condition was assessed at t0 with
a questionnaire listing 31 common illnesses from
the Health Survey of Statistics Netherlands, among
them, diabetes mellitus, chronic obstructive lung
disease, cardiac disease, arthritis of knee or hip and
cancer (26).
Sociodemographic characteristics were assessed
in structured face-to-face interviews. The following
variables were used: female gender, age (in years),
education, living with a partner, born in the
Netherlands or elsewhere, employment status.
Resource use and costing
All costs are expressed in dollars (US$) for the
reference year 2003. For conversion from euros
(the currency in The Netherlands) to US$, we used
Purchasing Power Parities (PPPs), which are cur-
rency conversion rates that both convert currency
and equalize the purchasing power of diﬀerent
currencies. The Organization for Economic
Cooperation and Development (OECD) equates
US$ 1.00 to € 0.920 in The Netherlands in 2003 (cf.
http://www.oecd.org/std/ppp).
Because the time frame of this study is restricted
to this single year, we did not correct for inﬂation
and did not discount costs. Conceptually, the
following types of costs can be distinguished.
Direct medical costs are the costs of health
service resource use. All direct medical costs refer
to costs made in the mental healthcare sector in the
Netherlands. There were only three exceptions: we
also included GP costs, costs of social work and
physiotherapy. This was done because people with
mental problems often make use of their services.
Information on the subjects use of health services
was obtained with a prototype version of the
Trimbos and Institute of Medical Technology
Assessment Cost questionnaire for Psychiatry
(TIC-P) (27). This questionnaire registers the
number of general practitioner visits, sessions
with psychiatrists, hospital days, etc. In a next
step, medical resource use was calculated by
multiplying the number of health service units
(consultations, hospital days, etc.) by their integral
cost price (28).
To these costs we added the costs of pharmaco-
logical interventions as the cost price per standard
daily dose (obtained from the Pharmaceutical
Compass at http://www.fk.cvz.nl), plus 6% VAT,
multiplied by the number of prescription days, plus
the pharmacist’s dispensing costs of US$ 7.91 per
prescription.
Direct non-medical costs arise when patients
travel to health service providers and pay for
parking. In the Netherlands, the average travel
distance between a random address and a general
practitioner’s practice is 1.8 km. Travel distances
to other health services are also known (28). This
information was combined with the information
about actual use of health services. Travel distan-
ces were valued at US$ 0.17 per km and 1 h
parking time was valued at US$ 2.70. To this we
added the costs of the patients time spent in travel,
waiting and in treatment at US$ 9.00 per hour (see
Appendix 1).
Indirect non-medical costs arise when production
losses occur due to illness. Subjects were asked
about the number of days spent in bed due to
illness. These days in bed are split according to
workdays (resulting in production losses due
to loss of work days) and days spent in bed while
not having to work (resulting in production losses
in the domestic sphere). To value a lost day in a
paid job we used the costs which represent the age
and gender-speciﬁc monetary counter-value of
production losses that occur during absence from
work (29).
For persons too ill to perform domestic tasks,
these costs were valued at the black market price of
domestic help at US$ 9.00 per hour. The black
market price is used for these costs because they
are assumed to reﬂect the true costs.
The cost calculations were conducted in accord-
ance with the latest Dutch guideline for health
economic evaluations (28), which closely resembles
other international guidelines (30–32).
Analysis
Our analytical strategy consisted of establishing a
baseline of the costs across diﬀerent diagnostic
categories, after which we computed the additional
or excess costs over and above that base rate. The
base rate consists of the costs which are generated
annually by every person, on average.
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First, we conducted a series of multiple regres-
sion analyses. In the ﬁrst analysis, the overall
excess per capita costs (the costs above the base
rate) were used as dependent variable, while the
presence of minor depression, major depression,
dysthymia, any anxiety, any alcohol-related disor-
der and somatic disorders were used as predictors.
This allowed us to examine the costs of minor
depression, while controlling for other common
mental disorders. In the second regression analysis,
we used direct medical excess costs as dependent
variable and the same variables as predictors. In
the third and fourth regression analyses, the direct
non-medical and the indirect non-medical costs
were used as the dependent variables.
To account for initial non-response and drop-
out, corrective weights were used. After weighting,
the sample followed exactly the same multivariate
distribution over age, sex, civil status and urban-
ization as the population according to Statistics
Netherlands (downloadable from http://
www.cbs.nl).
To account for the possible non-normality of the
cost data, sample errors, 95% conﬁdence intervals
(CIs) and P-values were based on 1000 bootstrap
replications, while at each bootstrap step robust
sample errors were obtained using the ﬁrst-order
Tailor-series linearization method. The latter was
done to obtain correct 95% CIs and P-values
under weighting.
The bootstrap method is often used for getting
95% CIs in economic studies, especially when it is
expected that standard statistical (asymptotic)
theory may not hold – as might have been the
case for the non-normally distributed cost data.
For our data we found that the 95% bootstrap
intervals were nearly identical with the 95% CIs
that were obtained with help of the robust standard
errors (based on the Hubert–White sandwich
method). So, there is no appreciable diﬀerence.
Nevertheless, we lend preference to the bootstrap
intervals, because they are more robust.
Next, we recalculated the per capita costs into
the costs per 1 million inhabitants (on the basis of
the societal costs per capita and the prevalence
rates for each disorder). For these costs per
1 million inhabitants, we used the prevalence
rates of mental disorders as reported earlier (2, 21).
Then we examined whether the costs of minor
depression were related to the number of depres-
sive symptoms. We devised three categories of
minor depression (with two, three or four symp-
toms). We then regressed the total societal per
capita costs on these three types of minor depres-
sion, major depression, dysthymia, any anxiety
disorder and any alcohol-related disorder, while
adjusting for somatic illnesses. Again, we recalcu-
lated the per capita costs of each of these three
types of minor depression into the costs per
1 million inhabitants.
To examine whether an increase in number of
symptoms in minor depression was related to an
increase in costs, we conducted a new regression
analysis with the economic costs as dependent
variable and the number of symptoms as predic-
tor, while controlling for other common mental
disorders and for somatic disorders (P for linear
trend).
Finally, we examined whether the excess costs of
minor depression were related to speciﬁc symp-
toms. We made a new variable indicating whether
the subject had minor depression with lack of
appetite (one of the symptoms of depressive
disorders) or minor depression without lack of
appetite. Then we entered both variables as
predictors in a multivariate regression analysis
(while partialling out the excess costs of major
depression, dysthymia, any anxiety and any alco-
hol-related disorder, and adjusting for the presence
of somatic disorders). We repeated this procedure
for every symptom of depression. Because we
found no signiﬁcant eﬀects and because the stand-
ard errors were large (as generally occurs in cost-
of-illness studies in psychiatric disorders), we
decided to calculate both the 95% CIs and 90%
CIs (all based on 1000 bootstrap replications).
All analyses were conducted with Stata version
7.0/SE (Stata Corp., College Station, TX, USA).
Results
Per capita costs and costs at the population level
Table 1 shows that the annual excess per capita
costs of having minor depression is, on average,
US$ 2141 (SE ¼ 708; 95% CI ¼ 753–3529), while
the excess costs of major depression are US$ 3313
(SE ¼ 1061; 95% CI ¼ 1234–5390).
As indicated earlier, these costs should be
interpreted as the excess costs of the disorder,
because every person generates, on average, a base
rate of US$ 1023 annually. The actual costs when
someone experiences an episode of minor depres-
sion are in a given year US$ 2141 + US$ 1023 ¼
US$ 3164. The annual direct medical and direct
non-medical excess costs are very small and non-
signiﬁcant for minor depression, indicating that
subjects with minor depression receive hardly any
excess professional help compared to subjects
without mental or other disorders. The indirect
non-medical costs are signiﬁcantly diﬀerent from
the base rate and are relatively high (US$ 2101).
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These latter costs approach the costs of major
depression (US$ 2535).
We used the per capita costs to calculate the
costs per 1 million inhabitants aged 18–65 years.
This includes all cost categories (health service
uptake, out-of-pocket costs, production losses; and
is equivalent to the per capita excess costs · pre-
valence · 1 000 000). Table 2 shows that the costs
of minor depression are 160 million dollars per
year, which is somewhat less than the 192 million
dollars per year for major depression. Thus, the
economic costs associated with both disorders are
considerable.
Costs associated with the number of symptoms
We examined the possibility that an increasing
number of symptoms is associated with higher per
capita costs by calculating the per capita costs
associated with minor depression with two symp-
toms, three and with four symptoms. The results
are presented in Fig. 1. The per capita costs
increased signiﬁcantly with the increasing number
of symptoms (two symptoms: US$ 987, three: US$
2866 and four: US$ 3474; P for linear trend
<0.001).
We also calculated the number of subjects with
minor depression with two, three and four symp-
toms, and the total annual costs per 1 million
inhabitants. Although the number of subjects with
these three types of minor depression decreases
somewhat with the increase in the number of
symptoms (prevalence of 0.025 for two symptoms,
0.026 for three and 0.023 for four symptoms;
overall prevalence 0.075), the total annual costs per
1 million inhabitants increases strongly with the
increase in the number of symptoms.
Costs associated with specific symptoms
We found only few indications that speciﬁc symp-
toms of minor depression were associated with
increased per capita costs. None of the analyses
reached a signiﬁcance level of 0.05. Because the
standard errors were large, we also calculated the
90% CIs (Table 3). We found a trend (p < 0.1)
indicating that the costs associated with minor
depression in which lack of appetite was present
were lower than the costs associated with minor
depression without lack of appetite. Furthermore,
Table 1. Annual per capita costs* (in US$) by DSM-III-R disorder (sample errors and 95% confidence intervals,  weighted analysis, n ¼ 5491)
Disorder
Total Direct medical Direct non-medical Indirect non-medical
Costs SE 95% CI Costs SE 95% CI Costs SE 95% CI Costs SE 95% CI
Minor depression 2141 708 753–3529 10 27 )42–63 29 24 )18–76 2101 723 684–3518
Major depression 3313 1061 1234–5390 478 134 215–740 313 138 42–583 2535 1013 549–4520
Dysthymia 13 679 3688 6450–20 907 349 473 )578–1276 )49 184 )409–311 13 373 3783 5959–20 787
Any anxiety disorder 3190 916 1393–4987 278 172 )60–615 238 109 25–451 2671 841 1022–4320
Any substance-related disorder 1369 880 )357–3094 161 109 )53–375 34 31 )34–101 1172 880 )555–2898
Somatic illness 3265 260 2756–3774 27 18 )10–63 13 13 )13–39 3224 259 2718–3731
Base rate (constant) 1023 147 735–1310 8 15 )21–37 8 13 )18–34 1008 150 714–1302
*Costs are the societal costs, including direct medical, direct non-medical and indirect non-medical costs.
(Robust) sample errors and 95% CIs are based on 1000 bootstraps.
The sum of the direct medical, direct non-medical and indirect non-medical costs is not exactly the same as the total costs, because each type of cost was estimated
separately and may vary slightly.
Table 2. Annual costs (in million US$) attributable to prevalent cases per 1 million
inhabitants aged 18–65 years
Prevalence
(in %)
Costs
(in million US$)
Minor depression 7.5 160.4
Major depression 5.8 192.2
Dysthymia 2.3 314.6
Any anxiety disorder 12.4 395.6
Any substance-related disorder 8.9 121.9
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Fig. 1. Annual per capita costs of three types of minor
depression (with one, two or three symptoms plus the key
symptom) and total annual costs of these three types of minor
depression per 1 million inhabitants.
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there was a trend indicating that feelings of
worthlessness and guilt in minor depression were
associated with higher per capita costs.
Discussion
In the present study the economic costs associated
with minor depression were found to be consider-
able, and approaching the costs of major depres-
sion. Per million inhabitants, the excess costs were
about 160 million dollars, compared to about
190 million dollars for major depression. Minor
depression was hardly associated with increased
direct medical and direct non-medical costs, and
virtually all excess costs were those associated with
production losses due to illness (i.e. indirect non-
medical costs). This indicates that subjects with
minor depression do not receive more professional
help than the average person, which is in contrast
to other studies reporting that minor depression is
associated with more use of mental health services
(2, 5). However, most research in this area has
focused on subjects who actually receive profes-
sional help and have not used data from the
general population.
However, in an earlier analysis of the same data,
we found that minor depression was associated
with increased use of services (2). The reason for
this discrepancy is that in the present study we
controlled for comorbid mental disorders, which
was not done in our earlier study.
In the present study the per capita excess costs of
major depression were substantially higher than
those of minor depression, but because the preval-
ence of minor depression was higher, the total costs
per million inhabitants were similar in both disor-
ders. This is an important ﬁnding from a public
health perspective: At the individual level minor
depression costs less, but at the population level
the costs are considerable and approach those of
major depression. This suggests that large-scale
treatment of minor depression will probably result
in increased medical costs, but may be cost-
eﬀective from a societal perspective.
There was evidence to support our hypothesis
that a larger number of symptoms of depression
are associated with higher excess per capita costs in
minor depression. Because most excess costs are
non-medical costs, this suggests that a larger
number of symptoms is associated with more role
limitations and more production losses.
Apart from the number of symptoms, the
excess per capita costs could also be associated
with speciﬁc symptoms. On examination we found
some (contra-intuitive) indications that lack of
appetite may be associated with lower costs. In
addition, feelings of worthlessness may be associ-
ated with higher costs. These latter results indicate
that it is not so much the type of symptom, but
the number of symptoms which is associated with
excess costs.
This study has several strengths and limitations.
Strengths include the relatively large, representa-
tive community sample (n ¼ 5504), the inclusion of
direct medical and non-medical costs, as well as the
indirect non-medical costs, and the use of well-
validated diagnostic instruments to assess the
presence of mental disorders. There are, however,
also some limitations. First, we used data from the
second measurement point of the NEMESIS study;
at this measurement point some attrition had taken
place which may have distorted the results. How-
ever, corrective weights were used to control for
selective drop-out.
Second, we used a deﬁnition of minor depression
which approached the DSM-IV deﬁnition. How-
ever, whereas the DSM-IV deﬁnition stipulates
that the symptoms should co-occur during
2 weeks, our deﬁnition deﬁned minor depression
as having had the symptoms during 1 year. Thus in
some cases, the symptoms may have occurred at
Table 3. Annual per capita costs (in US$) of minor depression with and without
specific symptoms (sample errors and 90% confidence intervals,  weighted
analysis, n ¼ 5491)
Symptom Costs§ SE– 90% CI
Change in appetite
Yes )421 1015 )2091–1250
No 2801 825** 1442–4159
Sleeping problems
Yes 2379 1064* 628–4131
No 1973 949* 412–3534
Agitation, restlessness
Yes 1363 2784 )3216–5944
No 2169 769** 904–3433
Fatigue, lack of energy
Yes 2404 1262 328–4481
No 2016 860* 602–3431
Worthlessness, guilt
Yes 8161 3132** 3010–13 312
No 1210 650 140–2279
Concentration problems
Yes 885 1053 )848–2617
No 2712 928** 1186–4238
Thoughts of death, suicide
Yes 2994 1141** 115–4871
No 1510 904 23–2998
Costs are the societal costs, including direct medical, direct non-medical and
indirect non-medical costs.
(Robust) sample errors and 90% confidence intervals are based on 1000 boot-
straps.
§The sum of the direct medical, direct non-medical and indirect non-medical costs
is not exactly the same as the total costs, because each type of cost was esti-
mated separately and may vary slightly.
–* and ** indicate that the costs differ significantly from the mean costs;
*p < 0.05; **p < 0.01.
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diﬀerent times during the past years. This may
have lead to misclassiﬁcation in some cases: some
participants may have been diagnosed with minor
depression while they did not experience all the
symptoms simultaneously. This type of misclassi-
ﬁcation is especially important when the diagnosis
spans longer periods of time (for instance when
studying the life time occurrence of disorders). In a
study of the 1-year occurrence of disorders it is
much less likely to have an eﬀect. However, some
misclassiﬁcation may have occurred. The eﬀect
would be that participants with less than the
required symptoms were classiﬁed as minor depres-
sion, which would probably lead to an underesti-
mation of the true costs of minor depression.
Third, although our number of subjects was
large, it was relatively small for economic studies
(33). This resulted in large standard errors and
conﬁdence intervals.
The costs reported in this paper should be
interpreted as conservative estimates for the fol-
lowing reasons. First, the medical costs that were
considered in this study were limited to those
related to mental health services and psychophar-
maca, whereas it is well known that mental
disorders also generate medical costs outside the
sector of mental health services (34). Second, the
cost calculations were based on self-reported med-
ical consumption, which is known to result in an
underestimate of the medical consumption and the
corresponding costs (35). Third, people who are ill
but still go to their job may work less eﬃciently,
resulting in production losses; such production
losses are not included in this study, but can be
substantial.(36, 37).
This study has shown that minor depression is
not only an important health problem but also
involves considerable economic costs, approaching
those of major depression. From a public health
point of view, it is important to continue the
attempts to develop treatments for minor depres-
sion and to test their eﬀects (38, 39).
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Appendix 1
Table 1. Direct medical and direct non-medical costs by health
service type (in 2003 US$)
Health service type
Direct medical costs Direct non-medical
Unit Cost price* km, P, h Cost price
Medical doctor Consult 22,00 1.8 km, 1 h 12.10
Medical specialist Consult 106.50 7 km, 2 h 22.00
Regional mental health service Contact 134.80 10 km, 3 h 31.50
Regional addiction service§ Contact 134.80 10 km, 3 h 31.50
Mental hospital – out-patient Consult 95.70 12 km, 4 h 40.40
Mental hospital – day care Contact 135.90 12 km, 4 h 40.40
Mental hospital – in-patient Day 271.80 8 h 72.20
General hospital – out-patient Consult 60.90 7 km, 3 h 31.00
General hospital – day care Contact 248.90 7 km, 4 h 40.00
General hospital – in-patient Day 366.30 8 h 72.20
Teaching hospital – out-patient Consult 108.70 12 km, 3 h 31.80
University hospital – day care Contact 248.90 12 km, 4 h 40.90
University hospital – in-patient Day 517.40 8 h 72.20
Private practice psychotherapist Session 82.60 5 km, 2 h 21.60
Social worker– Contact 48.90 7 km, 3 h 31.00
Physiotherapist Contact 24.70 1.8 km, 2 h 21.10
Home care Hour 33.40 0 km, 0 h 0.00
Informal care (family, friends)** Hour 9.00 0 km, 0 h 0.00
*Integral unit cost prices (28).
Based on average distances (in km) and travel + waiting + treatment times (in h)
for receiving treatment [cf. (28)].
Costs of 1 km ¼ US$ 0.17, parking ¼ US$ 2.70, 1 h time ¼ US$ 9.00 (28).
§Valued as out-patient mental health services.
–From DFL 77.00 in 1993, converted into dollars, indexed for 2003 (cf. http://
www.cbs.nl) and rounded.
**Valued as domestic help [cf. (28)].
Table 2. Indirect non-medical costs: average cost of production
losses for persons in paid employment (in US$ per h) by sex
and age*
Age (year) Men Women
15–24 22.27 21.82
25–34 35.59 32.48
35–44 41.41 36.52
45–54 49.32 37.19
55–64 51.98 39.58
65+ 51.98 39.58
*According to the friction costs method [cf. (28)].
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